GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Market cap $957.2M
Insiders sold $322K net in the last 90 days ·3 sellers, 0 buyers· 1 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 6, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Oct 6, 2026
Bowen Matthew
Monte Rosa Therapeutics, Inc. (GLUE) has 33 SEC Form 4 filings (63 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Oct 6, 2026.
Inside the rolling window, 8 insiders at Monte Rosa Therapeutics, Inc. reported no open-market purchases and 33 open-market sales totaling $4.1M. The most active filer is President & CEO Warmuth Markus with 7 filings. Insiders have net sold $2.9M over the trailing 6 months. The most recent open-market filing is a sale of 13 shares by Principal Accounting Officer Bowen Matthew, dated Oct 5, 2026, worth $137.
- Industry:Biotechnology
- CEO:Markus Warmuth
- Employees:173
- HQ:Boston, MA, US
- IPO:2021-06-24
| Source | |||||||
|---|---|---|---|---|---|---|---|
Bowen MatthewFirst filing | Principal Accounting Officer | Sale | 13 | $137 | Oct 6 | +13.7% | SEC ↗ |
| President & CEO | Sale | 9,500 | $220K | Jul 17 | -54.3% | SEC ↗ | |
| Chief Operating Officer | Sale | 4,351 | $102K | Jul 16 | -51.6% | SEC ↗ | |
| Chief Scientific Officer | Sale | 6,000 | $140K | Jul 7 | -54.0% | SEC ↗ | |
| Chief Medical Officer | Sale | 5,407 | $132K | Jul 1 | -53.3% | SEC ↗ | |
| Chief Medical Officer | Sale | 6,000 | $138K | Jun 30 | -53.6% | SEC ↗ | |
| Director | Sale | 10,000 | $231K | Jun 30 | -53.6% | SEC ↗ | |
Janku FilipFirst in 4 months | Chief Medical Officer | Sale | 11,845 | $240K | Jun 25 | -48.2% | SEC ↗ |
Janku FilipFirst in 4 months | Chief Medical Officer | Sale | 30,000 | $643K | Jun 25 | -48.2% | SEC ↗ |
| Chief Scientific Officer | Sale | 3,000 | $60K | Jun 25 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 2,175 | $44K | Jun 25 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,000 | $57K | Jun 18 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 2,176 | $41K | Jun 18 | — | SEC ↗ | |
| President & CEO | Sale | 5,466 | $106K | Jun 2 | — | SEC ↗ | |
Townson SharonFirst in 5 months | Chief Scientific Officer | Sale | 6,000 | $119K | Jun 1 | — | SEC ↗ |
| Chief Operating Officer | Sale | 2,175 | $44K | May 28 | — | SEC ↗ | |
Champoux JenniferFirst in 5 months | Chief Operating Officer | Sale | 2,176 | $41K | May 26 | — | SEC ↗ |
Manning Anthony M.First filing | Director | Sale | 10,000 | $180K | May 22 | — | SEC ↗ |
| President & CEO | Sale | 5,467 | $103K | May 5 | — | SEC ↗ | |
| President & CEO | Sale | 8,000 | $141K | Apr 15 | — | SEC ↗ | |
Nickson PhilipFirst in 3 months | Chief Business & Legal Officer | Sale | 5,845 | $103K | Apr 10 | — | SEC ↗ |
| Principal Accounting Officer | Sale | 139 | $2K | Mar 5 | — | SEC ↗ | |
| President & CEO | Sale | 5,466 | $98K | Mar 4 | — | SEC ↗ | |
| Principal Accounting Officer | Sale | 25,164 | $456K | Mar 2 | — | SEC ↗ | |
| Principal Accounting Officer | Sale | 536 | $9K | Mar 2 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does GLUE have?
Monte Rosa Therapeutics, Inc. (GLUE) has 33 SEC Form 4 filings (63 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Oct 6, 2026.
When was the most recent SEC Form 4 filing for GLUE?
The most recent Form 4 filing for GLUE on Tracefour is dated Oct 6, 2026.
Who is the most active insider at GLUE?
The most active SEC Form 4 filer at GLUE in the rolling window is President & CEO Warmuth Markus, with 7 filings.
What is the net insider flow at GLUE over the last 6 months?
Over the trailing 180 days, insiders at GLUE have net sold $2.9M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at GLUE in the current window?
Inside the rolling window, insiders at GLUE bought $0 and sold $4.1M based on SEC Form 4 filings.
Can I get alerts for GLUE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Monte Rosa Therapeutics, Inc. (GLUE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Monte Rosa Therapeutics, Inc. is in the Healthcare sector.